由于临床状况不佳，心脏肿瘤患者可能对手术切除提出挑战。超声心动图引导下的经心尖射频消融治疗心脏肿瘤（TARFACT）可能提供一种微创姑息治疗选择。本研究旨在评估 TARFACT 的安全性和有效性。五名患有心脏肿瘤（粘液性脂肪肉瘤、心肌肥厚伴炎性细胞浸润肿块、包括纤维组织肿瘤增生、心肌透明细胞肉瘤和心脏横纹肌瘤）。所有患者均接受 TARFACT 治疗，并进行心电图、超声心动图、生化分析和病理证实等评估。所有患者的中位随访时间为 9（4-12）个月。 3 名幸存患者在最后一次随访时仍存活（分别为 9、12 和 12 个月），而 2 名晚期肿瘤患者在 TARFACT 治疗后分别存活 6 个月和 13 个月。 TARFACT 治疗后，所有患者的肿瘤尺寸均显着减小：平均长度从 6.7 ± 2.0 cm 减小至 4.7 ± 1.8 cm（P = 0.007）；平均宽度从 5.0 ± 2.1 cm 减少到 2.5 ± 0.7 cm (P = 0.041)。 NYHA 功能等级也有所改善：中位数 (IQR) 从 3.0 (1.5) 下降到 2.0 (1.0) (P = 0.038)，超声心动图上的峰值 E 波显示平均从 64.4 ± 15.7 cm/s 增加到 76.6 ± 18.6 cm/s s (P = 0.008)，NT-pro BNP 水平中位数 (IQR) 从 115.7 (252.1) pg/mL 降低至 55.0 (121.6) pg/mL (P = 0.043)。TARFACT 是一种新型姑息治疗选择心脏肿瘤，减少可触及的肿瘤并改善初步患者组的临床症状。 （心脏肿瘤介入[射频/激光消融]治疗[CTIH]；NCT02815553）。© 2024 作者。

Patients with cardiac tumors may present challenges for surgical resection due to poor clinical condition. Echocardiography-guided transapical radiofrequency ablation for cardiac tumors (TARFACT) potentially offers a less invasive palliative therapy option.This study aimed to evaluate the safety and efficacy of TARFACT.Five patients with cardiac tumors (mucinous liposarcoma, myocardial hypertrophy with inflammatory cell infiltration mass, fibrous tissue tumor hyperplasia, myocardial clear cell sarcoma, and cardiac rhabdomyoma) were included. All patients underwent TARFACT and were assessed with electrocardiogram, echocardiographic imaging, biochemical analysis, and pathological confirmation.The median follow-up for all patients was 9 (range 4-12) months. Three surviving patients were alive at their last follow-up (9, 12, and 12 months, respectively), whereas 2 patients with late-stage tumors survived 6 months and 13 months after TARFACT, respectively. After TARFACT, all patients showed significant reductions in tumor size: the mean length decreased from 6.7 ± 2.0 cm to 4.7 ± 1.8 cm (P = 0.007); and the mean width decreased from 5.0 ± 2.1 cm to 2.5 ± 0.7 cm (P = 0.041). NYHA functional class also improved: median (IQR) decreased from 3.0 (1.5) to 2.0 (1.0) (P = 0.038), Peak E-wave on echocardiography showed a mean increase from 64.4 ± 15.7 cm/s to 76.6 ± 18.6 cm/s (P = 0.008), and NT-pro BNP levels had a median (IQR) reduction from 115.7 (252.1) pg/mL to 55.0 (121.6) pg/mL (P = 0.043).TARFACT is a novel palliative treatment option for cardiac tumors, reducing accessible tumors and improving clinical symptoms in a preliminary group of patients. (Cardiac Tumors Interventional [Radio Frequency/Laser Ablation] Therapy [CTIH]; NCT02815553).© 2024 The Authors.